Status:
COMPLETED
A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Acute Pain
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VX-708 in healthy participants.
Detailed Description
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable ...
Eligibility Criteria
Inclusion
- Key
- Male and female of non-childbearing potential are eligible
- Body mass index (BMI) of 18.0 to 32.0 kilograms per meter square (kg/m\^2)
- A total body weight greater than (\>) 50 kg
- Key
Exclusion
- History of febrile illness or other acute illness within 14 days before the first dose of study drug
- Any condition possibly affecting drug absorption, distribution, metabolism, or excretion
- History of cardiac dysrhythmias
- Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
April 8 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 14 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05347394
Start Date
April 8 2022
End Date
April 14 2023
Last Update
May 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MAC Clinical Research
Manchester, United Kingdom